Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.
The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.
This report provides a complete quantitative data and qualitative analysis on the global market for Graft Versus Host Disease (GVHD) Treatment. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Graft Versus Host Disease (GVHD) Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Graft Versus Host Disease (GVHD) Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Graft Versus Host Disease (GVHD) Treatment, including the following market information:
Global Graft Versus Host Disease (GVHD) Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Graft Versus Host Disease (GVHD) Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Graft Versus Host Disease (GVHD) Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Graft Versus Host Disease (GVHD) Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Bristol-Myers Squibb, Abbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Caladrius, Eli Lilly, GlaxoSmithKline, Glenmark, Kadmon Holdings, Osiris Therapeutics, Sanofi, Takeda, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors
Thalidomide
Etanercept
Based on the Application:
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Graft Versus Host Disease (GVHD) Treatment Industry
1.7 COVID-19 Impact: Graft Versus Host Disease (GVHD) Treatment Market Trends
2 Global Graft Versus Host Disease (GVHD) Treatment Quarterly Market Size Analysis
2.1 Graft Versus Host Disease (GVHD) Treatment Business Impact Assessment - COVID-19
2.1.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Graft Versus Host Disease (GVHD) Treatment Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Graft Versus Host Disease (GVHD) Treatment Quarterly Market Size, 2019 VS 2020
3.2 By Players, Graft Versus Host Disease (GVHD) Treatment Headquarters and Area Served
3.3 Date of Key Players Enter into Graft Versus Host Disease (GVHD) Treatment Market
3.4 Key Players Graft Versus Host Disease (GVHD) Treatment Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Graft Versus Host Disease (GVHD) Treatment Segments, By Type
4.1 Introduction
1.4.1 Monoclonal Antibodies
1.4.2 MTOR Inhibitors
1.4.3 Tyrosine Kinase Inhibitors
1.4.4 Thalidomide
1.4.5 Etanercept
4.2 By Type, Global Graft Versus Host Disease (GVHD) Treatment Market Size, 2019-2021
5 Impact of Covid-19 on Graft Versus Host Disease (GVHD) Treatment Segments, By Application
5.1 Overview
5.5.1 Acute Graft Versus Host Disease (aGvHD)
5.5.2 Chronic Graft Versus Host Disease (cGvHD)
5.2 By Application, Global Graft Versus Host Disease (GVHD) Treatment Market Size, 2019-2021
5.2.1 By Application, Global Graft Versus Host Disease (GVHD) Treatment Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Business Overview
7.1.2 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.1.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
7.2 Abbott
7.2.1 Abbott Business Overview
7.2.2 Abbott Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.2.4 Abbott Response to COVID-19 and Related Developments
7.3 AbbVie
7.3.1 AbbVie Business Overview
7.3.2 AbbVie Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.3.4 AbbVie Response to COVID-19 and Related Developments
7.4 Allergan
7.4.1 Allergan Business Overview
7.4.2 Allergan Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.4.4 Allergan Response to COVID-19 and Related Developments
7.5 Anterogen
7.5.1 Anterogen Business Overview
7.5.2 Anterogen Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.5.4 Anterogen Response to COVID-19 and Related Developments
7.6 Astellas Pharma
7.6.1 Astellas Pharma Business Overview
7.6.2 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.6.4 Astellas Pharma Response to COVID-19 and Related Developments
7.7 Athersys
7.7.1 Athersys Business Overview
7.7.2 Athersys Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.7.4 Athersys Response to COVID-19 and Related Developments
7.8 Caladrius
7.8.1 Caladrius Business Overview
7.8.2 Caladrius Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.8.4 Caladrius Response to COVID-19 and Related Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Business Overview
7.9.2 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.9.4 Eli Lilly Response to COVID-19 and Related Developments
7.10 GlaxoSmithKline
7.10.1 GlaxoSmithKline Business Overview
7.10.2 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.10.4 GlaxoSmithKline Response to COVID-19 and Related Developments
7.11 Glenmark
7.11.1 Glenmark Business Overview
7.11.2 Glenmark Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.11.4 Glenmark Response to COVID-19 and Related Developments
7.12 Kadmon Holdings
7.12.1 Kadmon Holdings Business Overview
7.12.2 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.12.4 Kadmon Holdings Response to COVID-19 and Related Developments
7.13 Osiris Therapeutics
7.13.1 Osiris Therapeutics Business Overview
7.13.2 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.13.4 Osiris Therapeutics Response to COVID-19 and Related Developments
7.14 Sanofi
7.14.1 Sanofi Business Overview
7.14.2 Sanofi Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.14.4 Sanofi Response to COVID-19 and Related Developments
7.15 Takeda
7.15.1 Takeda Business Overview
7.15.2 Takeda Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.15.4 Takeda Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Graft Versus Host Disease (GVHD) Treatment Industry
1.7 COVID-19 Impact: Graft Versus Host Disease (GVHD) Treatment Market Trends
2 Global Graft Versus Host Disease (GVHD) Treatment Quarterly Market Size Analysis
2.1 Graft Versus Host Disease (GVHD) Treatment Business Impact Assessment - COVID-19
2.1.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Graft Versus Host Disease (GVHD) Treatment Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Graft Versus Host Disease (GVHD) Treatment Quarterly Market Size, 2019 VS 2020
3.2 By Players, Graft Versus Host Disease (GVHD) Treatment Headquarters and Area Served
3.3 Date of Key Players Enter into Graft Versus Host Disease (GVHD) Treatment Market
3.4 Key Players Graft Versus Host Disease (GVHD) Treatment Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Graft Versus Host Disease (GVHD) Treatment Segments, By Type
4.1 Introduction
1.4.1 Monoclonal Antibodies
1.4.2 MTOR Inhibitors
1.4.3 Tyrosine Kinase Inhibitors
1.4.4 Thalidomide
1.4.5 Etanercept
4.2 By Type, Global Graft Versus Host Disease (GVHD) Treatment Market Size, 2019-2021
5 Impact of Covid-19 on Graft Versus Host Disease (GVHD) Treatment Segments, By Application
5.1 Overview
5.5.1 Acute Graft Versus Host Disease (aGvHD)
5.5.2 Chronic Graft Versus Host Disease (cGvHD)
5.2 By Application, Global Graft Versus Host Disease (GVHD) Treatment Market Size, 2019-2021
5.2.1 By Application, Global Graft Versus Host Disease (GVHD) Treatment Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Business Overview
7.1.2 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.1.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
7.2 Abbott
7.2.1 Abbott Business Overview
7.2.2 Abbott Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.2.4 Abbott Response to COVID-19 and Related Developments
7.3 AbbVie
7.3.1 AbbVie Business Overview
7.3.2 AbbVie Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.3.4 AbbVie Response to COVID-19 and Related Developments
7.4 Allergan
7.4.1 Allergan Business Overview
7.4.2 Allergan Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.4.4 Allergan Response to COVID-19 and Related Developments
7.5 Anterogen
7.5.1 Anterogen Business Overview
7.5.2 Anterogen Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.5.4 Anterogen Response to COVID-19 and Related Developments
7.6 Astellas Pharma
7.6.1 Astellas Pharma Business Overview
7.6.2 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.6.4 Astellas Pharma Response to COVID-19 and Related Developments
7.7 Athersys
7.7.1 Athersys Business Overview
7.7.2 Athersys Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.7.4 Athersys Response to COVID-19 and Related Developments
7.8 Caladrius
7.8.1 Caladrius Business Overview
7.8.2 Caladrius Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.8.4 Caladrius Response to COVID-19 and Related Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Business Overview
7.9.2 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.9.4 Eli Lilly Response to COVID-19 and Related Developments
7.10 GlaxoSmithKline
7.10.1 GlaxoSmithKline Business Overview
7.10.2 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.10.4 GlaxoSmithKline Response to COVID-19 and Related Developments
7.11 Glenmark
7.11.1 Glenmark Business Overview
7.11.2 Glenmark Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.11.4 Glenmark Response to COVID-19 and Related Developments
7.12 Kadmon Holdings
7.12.1 Kadmon Holdings Business Overview
7.12.2 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.12.4 Kadmon Holdings Response to COVID-19 and Related Developments
7.13 Osiris Therapeutics
7.13.1 Osiris Therapeutics Business Overview
7.13.2 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.13.4 Osiris Therapeutics Response to COVID-19 and Related Developments
7.14 Sanofi
7.14.1 Sanofi Business Overview
7.14.2 Sanofi Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.14.4 Sanofi Response to COVID-19 and Related Developments
7.15 Takeda
7.15.1 Takeda Business Overview
7.15.2 Takeda Graft Versus Host Disease (GVHD) Treatment Quarterly Revenue, 2020
7.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Product Introduction
7.15.4 Takeda Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
